FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Julia A. Beaver, Amna Ibrahim et al.|Clinical Cancer Research|2020Cited by 185
Model-Informed Approach Supporting Approval of Adalimumab (HUMIRA) in Pediatric Patients with Ulcerative Colitis from a Regulatory PerspectiveRuo‐Jing Li, Yaning Wang, Lian Ma et al.|The AAPS Journal|2022Cited by 9